Related Experiment Videos
Nils Hoyer1,2, Elizabeth Bendstrup3,4, Jesper Rømhild Davidsen5,6
1Lungemedicinsk Forskningsenhed, Københavns Universitetshospital - Gentofte Hospital.
Ugeskrift for Laeger
|August 24, 2023
Summary
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and other fibrotic lung diseases involve sudden respiratory decline and lung damage. Current treatments offer limited survival benefits, highlighting a critical need for improved therapies.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Critical Care
Background:
- Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and other fibrotic interstitial lung diseases (AE-ILD) are characterized by rapid respiratory deterioration and new alveolar damage.
- These events significantly worsen patient prognosis, often leading to mortality within months.
Approach:
- This review synthesizes current diagnostic criteria and therapeutic strategies for AE-IPF and AE-ILD.
- Diagnostic reliance on high-resolution computed tomography (HRCT) findings, including new bilateral ground-glass opacities and consolidation, alongside exclusion of other causes like fluid overload.
Key Points:
- Diagnosis involves characteristic HRCT findings and ruling out cardiac or fluid issues.
- Treatment primarily involves glucocorticoids, supportive care, and palliative measures, despite limited evidence.
- Prognosis remains poor, with a median survival of only 2-4 months post-exacerbation.
Conclusions:
- AE-IPF and AE-ILD present a severe clinical challenge with high mortality.
- Current diagnostic approaches are based on imaging and clinical exclusion.
- Therapeutic options are limited, emphasizing the urgent need for novel treatment strategies and improved patient outcomes.